Skip to main content

Peer Review reports

From: The effects of lobbying on the FDA’s recall classification

Original Submission
7 Sep 2020 Submitted Original manuscript
16 Nov 2020 Reviewed Reviewer Report
11 Apr 2021 Reviewed Reviewer Report - Ken Bond
15 Apr 2021 Author responded Author comments - Yifan Zhou
Resubmission - Version 2
15 Apr 2021 Submitted Manuscript version 2
10 May 2021 Reviewed Reviewer Report
14 May 2021 Reviewed Reviewer Report - Ken Bond
1 Oct 2021 Reviewed Reviewer Report
12 Oct 2021 Author responded Author comments - Yifan Zhou
Resubmission - Version 3
12 Oct 2021 Submitted Manuscript version 3
23 Dec 2021 Reviewed Reviewer Report
24 May 2022 Author responded Author comments - Yifan Zhou
Resubmission - Version 4
24 May 2022 Submitted Manuscript version 4
6 Sep 2022 Author responded Author comments - Yifan Zhou
Resubmission - Version 5
6 Sep 2022 Submitted Manuscript version 5
10 Oct 2022 Author responded Author comments - Yifan Zhou
Resubmission - Version 6
10 Oct 2022 Submitted Manuscript version 6
3 Dec 2022 Author responded Author comments - Yifan Zhou
Resubmission - Version 7
3 Dec 2022 Submitted Manuscript version 7
8 Dec 2022 Author responded Author comments - Yifan Zhou
Resubmission - Version 8
8 Dec 2022 Submitted Manuscript version 8
3 Apr 2023 Author responded Author comments - Yifan Zhou
Resubmission - Version 9
3 Apr 2023 Submitted Manuscript version 9
Publishing
9 Jun 2023 Editorially accepted
20 Jun 2023 Article published 10.1186/s12910-023-00921-0

You can find further information about peer review here.

Back to article page